Comparison of Treatment for Endometrial Cancer

What we are studying

The purpose of this study is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating your type of cancer and to find out what side effects are caused by treatment with these drugs. The combination of paclitaxel, carboplatin and metformin in the treatment of advanced or recurrent endometrial cancer is investigational. In order to better determine if the addition of metformin to paclitaxel and carboplatin helps better treat endometrial cancer, half of the women in this study will receive metformin with paclitaxel and carboplatin and the other half will receive a placebo with paclitaxel and carboplatin. A placebo is a tablet or pill with no active ingredients.

Who we are studying

  • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Confirmed diagnosis of endometrial carcinoma
  • Have not received chemotherapy for treatment of endometrial cancer
  • Not be taking Metformin within the last 6 months

What is involved

  • Treatment with chemotherapy day 1 of each cycle (6 total cycles)
  • Treatment with metformin/placebo once daily for 7 cycles
  • Quality of Life Questionnaires

Contact Information

Study Coordinator
Melissa Swain, RN
Email
mswain@wakehealth.edu
Phone
336-716-9428

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.